Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | MC4R | P32245 | 1/20 | 0.61 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.61 |
| ▸ | MC3R | P41968 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.57 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.57 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.54 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.54 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.54 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyrazine Carboxylic Acid Hydrazide SCHEMBL18038330 | 0.98 | ADORA3 (0.59) | ADORA3TSHRMC4RADRA1AMC3R | |
| Pyrazine Carboxylic Acid Hydrazide SCHEMBL27792055 | 0.83 | RAB9A (0.51) | ADORA3TSHRMC4RADRA1AMC3R | |
| Pyrazine Carboxylic Acid Hydrazide SCHEMBL8856511 | 0.83 | SMN1; SMN2 (0.52) | TSHRKDM4ESMN1; SMN2HDAC3HDAC1 | |
| SCHEMBL5062627 | 0.83 | KDM4E (0.61) | ADORA3TSHRMC4RADRA1AMC3R | |
| SCHEMBL1412848 | 0.81 | KDM4E (0.59) | ADORA3TSHRMC4RADRA1AMC3R | |
| SCHEMBL11422057 | 0.80 | ADORA3 (0.62) | ADORA3TSHRMC4RADRA1AMC3R | |
| SCHEMBL31377918 | 0.80 | P2RX7 (0.52) | ADORA3KDM4EP2RX7CYP1A2CYP2C19 | |
| SCHEMBL10756114 | 0.80 | SMYD3 (0.52) | ADORA3TSHRMC4RADRA1AMC3R | |
| SCHEMBL733049 | 0.80 | KDM4E (0.63) | KDM4ESMN1; SMN2HDAC3HDAC1NPC1 | |
| SCHEMBL25718613 | 0.80 | SMN1; SMN2 (0.58) | ADORA3TSHRMC4RADRA1AMC3R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 269 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122080895-A | Polyglycolic acid composition and preparation method thereof, biodegradable polyester material and application thereof, and PGA temporary plugging ball and preparation method thereof | — | 2026-05-26 | — | — | CN | claimed |
| CN-119874681-A | Indole derivative, preparation method thereof and application of indole derivative in resisting liver cancer | 中国人民解放军北部战区总医院 | 2025-04-25 | — | — | CN | claimed |
| US-20240335442-A1 | N-ACYLHYDRAZONE COMPOUNDS CAPABLE OF INHIBITING NAV1.7 AND/OR NAV1.8, PROCESSES FOR THE PREPARATION THEREOF, COMPOSITIONS, USES, METHODS FOR TREATMENT USING SAME, AND KITS | UNIVERSIDADE FEDERAL DO RIO DE JANEIRO – UFRJ (BR) | 2024-10-10 | — | — | US | claimed |
| EP-4382100-A1 | N-ACYLHYDRAZONE COMPOUNDS CAPABLE OF INHIBITING NAV1.7 AND/OR NAV1.8, PROCESSES FOR THE PREPARATION THEREOF, COMPOSITIONS, USES, METHODS FOR TREATMENT USING SAME, AND KITS | Eurofarma Laboratórios S.A. (BR) | 2024-06-12 | — | — | EP | claimed |
| CN-118165279-A | Coordination polymer material, binuclear intermediate, preparation method and application thereof | 聊城大学 | 2024-06-11 | — | — | CN | claimed |
| CN-118076348-A | N-acylhydrazone compounds capable of inhibiting NAV 1.7 and/or NAV 1.8, methods of making, compositions, uses, methods of treatment and kits using the same | 欧罗法玛实验室股份公司 | 2024-05-24 | — | — | CN | claimed |
| CN-116621783-A | Pyrimidine hydrazide organic gel factor and preparation and application thereof | 上海应用技术大学 | 2023-08-22 | — | — | CN | claimed |
| CN-111527084-B | Isofuranone compounds useful as HPK1 inhibitors | 百时美施贵宝公司 | 2023-07-18 | — | — | CN | claimed |
| WO-2023010191-A1 | N-ACYLHYDRAZONE COMPOUNDS CAPABLE OF INHIBITING NAV1.7 AND/OR NAV1.8, PROCESSES FOR THE PREPARATION THEREOF, COMPOSITIONS, USES, METHODS FOR TREATMENT USING SAME, AND KITS | EUROFARMA LABORATÓRIOS S.A. (BR) | 2023-02-09 | — | — | WO | claimed |
| EP-3707138-B1 | ISOFURANONE COMPOUNDS USEFUL AS HPK1 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2022-07-13 | — | — | EP | claimed |
| CN-110372681-B | Application of self-assembled nano fluorescent probe for selectively detecting human serum albumin | 天津医科大学 | 2022-06-07 | — | — | CN | claimed |
| CN-112592339-B | 1,3, 4-oxadiazole-2 (3H) -thione-norfloxacin heterozygote and preparation method and application thereof | 广东省微生物研究所（广东省微生物分析检测中心） | 2022-06-07 | — | — | CN | claimed |
| CN-113416266-A | Aromatic hydrazide compound-cyclodextrin inclusion compound and preparation method thereof | 湖北工业大学 | 2021-09-21 | — | — | CN | claimed |
| CN-112592339-A | 1,3, 4-oxadiazole-2 (3H) -thione-norfloxacin heterozygote and preparation method and application thereof | 广东省微生物研究所（广东省微生物分析检测中心） | 2021-04-02 | — | — | CN | claimed |
| CN-112480087-A | Schiff base with aggregation-induced emission effect and preparation method thereof | 齐鲁工业大学 | 2021-03-12 | — | — | CN | claimed |
| CN-110372681-A | A kind of application of the self-assembled nanometer fluorescence probe for selective enumeration method human serum albumins | 天津医科大学 | 2019-10-25 | — | — | CN | claimed |
| CN-106432308-B | A kind of cerium schiff bases complex and its preparation method and application | 山西大学 | 2017-12-05 | — | — | CN | claimed |
| EP-0343866-A1 | Aminophenol derivatives | ICI AMERICAS INC. (US) | 1989-11-29 | — | — | EP | claimed |
| EP-0293171-A1 | Pyrazinamide derivatives | ICI AMERICAS INC. (US) | 1988-11-30 | — | — | EP | claimed |
| EP-0293170-A1 | Aminomethylphenolic pyrazines, their preparation and use | ICI AMERICAS INC. (US) | 1988-11-30 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240335442-A1 | N-ACYLHYDRAZONE COMPOUNDS CAPABLE OF INHIBITING NAV1.7 AND/OR NAV1.8, PROCESSES FOR THE PREPARATION THEREOF, COMPOSITIONS, USES, METHODS FOR TREATMENT USING SAME, AND KITS | SCN1A, SCN7A, SCN8A | ADORA3 1457/4885TSHR 3726/4885MC4R 1896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.